Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.leukres.2011.11.011PMID 22172461
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in RPS14 expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletion

  2010cited by this paper
• Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study

  2010cited by this paper
• Advances in the 5q- syndrome.

  2010cited by this paper
• Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

  2010cited by this paper
• Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality

  2009cited by this paper
• A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q− syndrome

  2009cited by this paper
• Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

  2008cited by this paper
• Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis

  2008cited by this paper
• Common deleted genes in the 5q− syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice

  2007cited by this paper
• Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

  2007cited by this paper
• Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients

  2007cited by this paper
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

  2006cited by this paper
• Efficacy of lenalidomide in myelodysplastic syndromes.

  2005cited by this paper
• Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

  2002cited by this paper
• Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

  2001cited by this paper
• Report of an international working group to standardize response criteria for myelodysplastic syndromes.

  2000cited by this paper
• Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

  1999cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• The 5q-syndrome.

  1994cited by this paper
• Proposals for the classification of the myelodysplastic syndromes

  1982cited by this paper
• Academic Editor: Frederick R.

  year unknowncited by this paper

• Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.

  2019cites this paper
• Refining remission evaluation in MDS with isolated del(5q)

  2018cites this paper
• Lenalidomide Therapy of Myelodysplastic Syndromes

  2013cites this paper
• MYELODYSPLASTIC SYNDROME WITH DEL(5Q) AND LENALIDOMIDE

  2013cites this paper